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Abstract
Changes in the expression and activity of lipid-
metabolizing enzymes, including the linoleic acid
(LA)–metabolizing enzyme 15-lipoxygenase-1 (15-LO-1),
may play a role in the development and progression of
human prostate carcinoma (PCa). We reported that
human 15-LO-1 (designated as leukocyte type 12-LO or
12/15-LO in mouse) is expressed in human prostate
and increased in PCa, particularly high-grade PCa.
Genetically engineered mouse (GEM) models of PCa
could facilitate the study of this gene and its regulation
and function in PCa progression. In this study, we
examine the protein expression and enzyme activity
levels of 12/15-LO associated with PCa progression in
the TRansgenic Adenocarcinoma of Mouse Prostate
(TRAMP) model of PCa. This GEM model develops
prostatic intraepithelial neoplasia (PIN), followed by
invasive gland-forming PCa and invasive and meta-
static less differentiated PCa, with neuroendocrine
(NE) differentiation (NE Ca). In the wild-type and
TRAMP prostates, the most prominent LA metabolite
was 13-hydroxyoctadecadienoic acid (13-HODE). Less-
er amounts of 12-hydroxyeicosatetraenoic acid and
15-hydroxyeicosatetraenoic acid (HETE) were made
from arachidonic acid (AA). In TRAMP prostates, 12/15-
LO activity was increased compared to wild type at
20, 29, 39, and 49 weeks, as assessed by LA conversion
to 13-HODE, and by AA conversion to 12/15-HETE,
respectively. Immunostaining demonstrated that the
increased capacity to generate 13-HODEwas paralleled
by an increase in neoplastic epithelial expression of
12/15-LO in PIN and invasive carcinomas. In conclu-
sion, although there is a basal 12/15-LO activity in the
wild-type mouse prostate, there is a marked increase in
the expression of 12/15-LO with TRAMP PCa progres-
sion, paralleling our previously reported increased
expression of the ortholog 15-LO-1 in high-grade
human PCa. Thus, 12/15-LO and LA metabolism in the
TRAMP model shares similarities to human PCa, and
may allow to confirm a role for LA metabolism and
other biologic functions of 15-LO-1 in human PCa. In
addition, the TRAMP model will serve as a tool for
testing the suitability of 12/15-LO—and ultimately
human 15-LO—as a therapeutic target during PCa
progression.
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Introduction
In the development and progression of prostate carcinoma
(PCa), precursor lesions such as high-grade prostatic intra-
epithelial neoplasia (HGPIN) in the peripheral zone evolve into
invasive carcinoma, with progression to more extensive organ-
confined tumors, and then to tumors that can penetrate the
prostatic capsule and invade locally or metastasize [1]. An
estimated 230,110 new cases of PCa will be detected in the
United States in 2004, and an estimated 29,900 PCa deaths
will occur (American Cancer Society, Facts and Figures 2004).
All currently adopted therapies for PCa have limitations, and
there is no cure for PCa leading to metastatic disease. Ad-
vanced and metastatic PCa commonly progresses to clinically
hormone-refractory disease (androgen insensitivity), limiting
treatment options in advanced disease (Ref. [1] and references
therein). Investigations to more completely understand the
development and progression of PCa have been difficult in
human patients because the cancer typically develops at an
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extremely slow pace, and, along with difficulties in tissue
sampling over a time period, this makes it practically impos-
sible to track the molecular changes that are associated with
the disease progression in patients. These characteristics
also pose a challenge for therapeutic trials, including those
based on targeting desirable genes or pathways that are
predicted to be causal during the earlier stages of the
disease.
Hence, genetically engineered mouse (GEM) models of
PCa are beginning to emerge as potentially powerful tools in
PCa research, allowing for correlation of molecular altera-
tions with tumor progression and design of appropriate
interventional trials based on blocking of stage-specific dis-
ease progression [2–4]. GEM models [5–9] [such as the
TRansgenic Adenocarcinoma of Mouse Prostate (TRAMP)
model generated using a prostate-selective short probasin
promoter and the SV40 early region [6,7], and long probasin
promoter SV40-large T antigen (LPB-Tag; LADY) generated
using the LPB-Tag [8,9] recapitulate certain key aspects of
human PCa [1]. These particular models, designed to po-
tentially mimic certain major initiating and secondary mo-
lecular changes in PCa, progress from PIN to invasive,
metastatic, and hormone-refractory PCa. Therefore, it is
reasonable to hypothesize that demonstrated therapeutic
interventions [2–4] that are effective in GEM models vali-
dated for molecular and pathologic changes similar to those
in human PCamay also be beneficial in human PCa patients.
Alterations in genes, such as lipoxygenases [5-LO [10],
12-LO [11], 15-lipoxygenase-1 (15-LO-1) [12–14], and 15-
LO-2 [15–18]] and cyclooxygenases (COX-1 and/or COX-2
[19–21]) that metabolize dietary lipids, have been postulated
to be key factors in PCa development or progression, and
represent attractive chemoprevention or therapeutic targets.
The precise role(s) of these enzymes (or enzymatic prod-
ucts) in PCa is an area of active investigation. Studies have
also suggested that one of the major reasons why Americans
suffer from high rates of cancers may be due to an imbalance
in the ratio of omega (N-3 to N-6) fatty acids [22–24]. An
important member of the N-6 group is linoleic acid [LA;
polyunsaturated fatty acid (PUFA), C18: 2n6], which is an
essential PUFA found in sunflower, safflower, canola, and
peanut oils. 15-LO-1 preferentially metabolizes LA [25]. The
human 15-LO-1 enzyme forms 13-hydroxyoctadecadienoic
acid (13-HODE) from LA, and its ortholog in mouse [i.e.,
12/15-LO enzyme (also known as leukocyte type 12-LO)]
forms a mixture of 12-HETE and 15-HETE from AA, res-
pectively [25,26]. Human 15-LO-1–derived 13-S-hydroxy-
octadecadienoic acid (13-S-HODE) can exert several
proneoplastic effects, including enhanced cellular prolifera-
tion [13,14,27–36]. We previously observed that 15-LO-1
expression is increased in human PCa compared to benign
prostate, particularly in high-grade PCa, further suggesting a
possible etiologic role in PCa progression [13]. We subse-
quently demonstrated that overexpression of 15-LO-1 in a
human PCa cell line, PC-3, produced aggressive tumors in
athymic mice, at least in part by promoting angiogenesis [14].
It should be noted that Shappell et al. [15,16] and Jack et al.
[17] have demonstrated that a distinct 15-lipoxygenase
(15-LO-2) is highly expressed in benign prostate, and re-
duced in HGPIN and PCa. 15-LO-2 converts its preferred
substrate AA to 15-S-hydroxyeicosatetraenoic acid (15-S-
HETE) [25], which could potentially inhibit the growth of PCa
cells by activating the anti– tumorigenic peroxisome prolifer-
ator–activated receptor g (PPARg) activity [37]. More re-
cently, 15-LO-2 was shown to be a negative cell cycle
regulator in normal prostate [18], and others have shown
that 15-LO-1 and 15-LO-2 have opposing pro–neoplastic
effects and anti–neoplastic effects, due at least in part to
the preferred formation of 13-HODE and 15-HETE, respec-
tively, by differential effects on MAPK and PPARg [36,38].
Thus, although a role for 15-LO-1 in other organ systems
remains to be more fully defined [39], in prostate, 15-LO-1
appears to behave distinctly different from 15-LO-2 in that
15-LO-1 specifically appears to be increased in PCa and
may contribute to PCa by promoting cell proliferation and
angiogenesis [14].
Although the ortholog of the human 15-LO-1 gene in the
mouse is 12/15-LO, for the human 15-LO-2 in mouse, it is
8-LO [25]. Surprisingly, 8-LO is absent in the mouse pros-
tate, but is specifically expressed in the skin [41]. As the
murine ortholog of 15-LO-1 enzyme has been identified [26],
TRAMP and LPB-Tag mouse models of PCa may allow for:
1) elucidation of the role(s) of 15-LO-1 (human)/12/15-LO
(mouse) in the development and progression of PCa; and
2) suitability of 15-LO-1 as a potential therapeutic target in
PCa. In the current study, expression of 12/15-LO was
investigated in wild-type mice, with PCa progression in
TRAMP mice achieved through a combination of enzyme
activity assays and immunohistochemistry analyses; results
compared with those that were previously observed in
human PCa.
Materials and Methods
Transgenic Mouse and Tissue Procurement
TRAMP mice hemizygous for the probasin promoter
SV40-large T antigen (PB-Tag) transgene were maintained
in a pure C57BL/6 background (Harlan Sprague Dawley,
Inc., Indianapolis, IN). TRAMP mice were bred to nontrans-
genic FVB mice (Harlan Sprague Dawley) to obtain non-
transgenic (wild type) and transgenic (C57BL/6 TRAMP
FVB) F1 (i.e., TRAMP) males. Experimental protocols were
reviewed and approved by the animal protocol review com-
mittee of the University of Pittsburgh. Fresh prostate tissues
procured from the wild-type (controls) and TRAMP mice
were placed in liquid nitrogen or immediately placed in
80jC freezer for subsequent protein extraction and en-
zyme activity assays. The remaining prostate tissue was
fixed in 10% formalin for routine histologic processing and
paraffin embedding for immunohistochemistry. Enzyme ac-
tivity was assessed in protein extracts of frozen prostate
tissues of wild-type and TRAMP mice at different ages,
corresponding to tumor progression in TRAMP. For this
study, prostates from wild-type and TRAMP mice at time
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points of 20 weeks (n = 5), 29 weeks (n = 5), 39 weeks
(n = 5), and 49 weeks (n = 3) were used.
Tissue Incubations and High-Performance Liquid Chroma-
tography (HPLC) Analysis
The 12/15-LO enzyme activity analyses were similarly
performed as previously described [13]. Briefly, 100 to
200 mg of mouse prostate tissues was individually homo-
genized in 4 vol of buffer (50mmol/l Triswith 100mmol/l NaCl,
100 mol/l CaCl2 pH 7.4, 1 mM phenylmethylsulfonyl fluo-
ride, 1 mM benzamidine, 10 mg/ml aprotinin, 10 mg/ml leu-
peptin, and 1 mg/ml pepstatin A). Cell homogenates (total
protein, 100 mg) were incubated at 30jC for 15 minutes in
600 ml of 50 mM Tris–HCl (pH 7.4) and 5 mM CaCl2 with
25 mM [14C] arachidonic acid (AA) or [14C]LA (1  06 cpm, 15
nmol; DuPont-New England Nuclear, Boston, MA) added from
stock solutions in ethanol (2.5% of final volume). Fatty acids
were isolated from the incubation buffer by a C18-PrepSep
solid phase extraction column (Waters, Milford, MA) after
acidification to pH 3.5 with acetic acid. The column was then
washed with acidified water, and the metabolite was eluted
with methanol, evaporated to dryness, and reconstituted with
HPLC solvent.
Reverse-phase HPLC analysis was performed using an
Ultrasphere ODS column (5 mm; 4.6  250 mm; Beckman,
Philadelphia, PA). All solvents were of HPLC grade and were
from Baker (Phillipsburg, NJ). The solvent system consisted
of a methanol/acetic acid/water gradient (80/1/19 vol/vol) at a
flow rate of 1.1 ml/min. Radioactivity was monitored using a
Flow Scintillation Analyzer (Packard, Palo Alto, CA) with
EcoLume (ICN Biochemicals, Costa Mesa, CA) as the liquid
scintillation cocktail. UV analysis was performed by monitor-
ing absorbance at 234 nm with a Waters 486 detector.
Authentic standards of 12-S-HETE, 15-S-HETE, and 13-S-
HODE (Cayman Chemical, Ann Arbor, MI) were simulta-
neously injected to monitor retention times. Percent (%)
conversion of [14C]LA and [14C]AA to their respective prod-
ucts was used to quantify the enzyme activity.
Pathology
The pathology of progressively severe neoplastic lesions
in TRAMP, including temporal progression in individual
lobes, has been previously described [1,6]. In the current
study, histopathologic descriptions (by hematoxylin and eo-
sin as well as immunohistochemistry) of neoplastic lesions
for the purpose of reporting immunostaining are in accord
with the recently reported pathologic criteria of the National
Cancer Institute (NCI) Mouse Models of Human Cancer
Consortium (MMHCC) [1]. Lesions previously reported as
HGPIN in TRAMP based on degree of nuclear atypia [1] are
herein referred to as PIN (with capacity to progress to
invasive carcinoma in MMHCC classification scheme, as
MMHCC guidelines currently recommend a natural history
classification over histologic PIN grading schemes).
Many of the lesions in TRAMP mice previously referred to
as well-differentiated adenocarcinoma were regarded by an
NCI-sponsored consensus conference as to more likely
represent an in situ lesion, and are referred to herein as
PIN [1]. Against this more uniform background lesion, archi-
tecturally distinct foci of atypical gland formations occasion-
ally extending into periprostatic stroma and having an
associated desmoplastic response are herein referred to
as adenocarcinoma, in accord with MMHCC guidelines [1].
In sections immunostained in the current series, such foci of
more unequivocal adenocarcinoma were uncommon and
focal compared to lesions more conservatively regarded as
PIN. Such foci generally showed immunostaining similar to
PIN, and are thus not separately reported in results (with
lesions at this stage of tumor progression referred to as
PIN/adenocarcinoma for the purpose of correlation with
results of immunostaining). Lesions composed of polypoid
proliferations of atypical epithelium and hypercellular stroma
with or without atypia and referred to previously as ‘‘phyl-
lodes-like’’ [1] (R. Barrios, N. Greenberg, personal commu-
nication) remain to be more completely characterized and
are referred to herein as epithelial and stromal hyperplasia,
in keeping with recent MMHCC recommendations [1].
Lesions previously reported as moderately and poorly differ-
entiated carcinoma in TRAMP [6,7] were typically seen to
coexist in larger unequivocally invasive carcinoma foci [1].
These lesions in TRAMP were regarded by an NCI-spon-
sored consensus conference as showing morphologic fea-
tures of neuroendocrine (NE) carcinoma, including small cell
carcinoma [1], as confirmed by immunohistochemistry and
electron microscopy in other models showing similar histo-
logic and cytologic features. In the current study, such foci
are referred to as invasive poorly differentiated carcinoma
with NE features of invasive NE carcinoma, in keeping with
MMHCC guidelines [1].
12/15-LO Immunohistochemistry
Paraffin-based immunohistochemical staining for the mu-
rine leukocyte 12-LO (12/15-LO) was performed as de-
scribed [26], and was reviewed and classified by the same
pathologist (Scott Shappell), who was blinded to the age of
the mice. The rabbit polyclonal antibody for murine L12-LO
was a generous gift from Dr. Colin Funk (University of
Pennsylvania) [23], and was used at a 1:50 dilution with
citrate steam antigen retrieval. Known expression in bron-
chial epithelium was used in mouse lung sections as a
positive control. Specificity of the immunostaining has previ-
ously been confirmed by performing immunostaining on lung
sections of a 12/15-LO (L12-LO) knockout mouse [40]. The
extent of immunostaining was assessed semiquantitatively
as 0 to 4+ as follows: 0, negative; 1+, rare immunostaining,
< 5% of cells in the section; 2+, focal, with immunostaining
in 5 to 25 of cells or up to 50% of epithelial cells within 5%
to 25% of gland profiles; 3+, immunostaining in 25% to 50%
of cells or extensive immunostaining in 25% to 50% of gland
profiles; 4+, diffuse, with immunostaining in > 50% of cells
or extensive immunostaining in > 50% of gland profiles.
Statistical Analyses
All experimental data are representative of at least five
different experiments (animals), except wherever noted.
Data are expressed as mean ± standard error (SE), and
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were compared by one-way ANOVA. The criterion for sta-
tistical significance was taken as P < .05.
Results
Enzymatic Activity of 12/15-LO and Conversion of LA and
AA in Wild-Type and TRAMP Prostates
Incubation of wild-type prostates with [14C]LA resulted in
the formation of [14C]13-HODE (Figures 1A and 2A), and
incubation with [14C]AA resulted in the formation of [14C]12-
HETE (a small amount of [14C]15-HETE) (Figures 1B
and 2B), as determined by reverse-phase HPLC. LA was
converted to one major metabolite, which coeluted with
standard 13-S-HODE at f20 minutes on reverse-phase
HPLC. AA was converted to one major metabolite, which
coeluted at f18minutes with standard 12-HETE, as well as
a minor metabolite, which coeluted at f19 minutes with
standard 15-HETE. Although not incompatible with the plate-
let 12-LO, this enzymatic activity is compatible with the
leukocyte type (L) 12-LO or 12/15-LO, which forms
13-HODE from LA [25], and forms much more 12-HETE
than 15-HETE from AA [25]. The 12/15-LO activity in the
wild-type and TRAMP mouse prostate tissues was as-
sessed by the respective percent (%) metabolite conversion
of LA to 13-HODE and of AA to 12/15-HETE, respectively
(Figure 3). Although LA was more efficiently metabolized
(c3-fold, averaged for all time points) compared to AA in
wild-type mice, the individual percentages for AA and LA
conversions did not appear to significantly change at all the
different ages analyzed (Figure 3). On the other hand, LA
was more efficiently metabolized (c4.9-fold, averaged for all
time points) compared to AA in TRAMP. The individual
percentages for AA conversion remained constant at 20
and 29 weeks and increased at 39 and 49 weeks, whereas
LA conversions appeared to increase gradually from 20 to
49 weeks (P < .03 for AA andP < .02 for LA at 39 weeks) at all
the different ages analyzed (Figure 3).
Increased Leukocyte 12/15-LO Immunostaining in Aging
TRAMP Mice
Consistent with the results of LA and AA incubations, im-
munostaining indicated that the leukocyte 12-LO (12/15-LO)
Figure 1. Representative LA and AA metabolism in wild-type nontransgenic 20-week mouse prostate. [14C]HODE and [14C]12/15-HETE formation in wild-type
mouse prostate (control) from 15-minute incubation with 25 M [14C]LA or [14C]AA. The solvent system consisted of a methanol/water gradient at a flow rate of
1.1 ml/min for reverse-phase HPLC analysis, with in-line radiodetection ( Y-axis as disintegrations per minute, or DPM). A prominent 13-HODE peak (panel A)
elutes at c 20 minutes, and a mixture of two metabolites coelutes at f18 to 19 minutes with standard 12-HETE and 12-HETE, respectively (12/15-HETE peak,
panel B) (X-axis as minutes). The unmetabolized LA and AA elutes are the prominent peaks at far right (in both panels A and B) eluting atc 54 and 55 minutes,
respectively. Also, a prominent peak of a mixture of prostaglandins (PGs) is seen eluting at c 6 to 7 minutes.
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was increased in the neoplastic prostate of TRAMP mice
(Figure 4). Similar to previous observations in wild-type
mouse prostate [40], no significant 12/15-LO immunostain-
ing was noted in the normal prostate of an 18-week wild-type
mouse (not shown). In contrast, focal to extensive 12/15-LO
immunostaining was present in the atypical epithelial cells of
PIN lesions in three of six TRAMP mice 18 to 29 weeks of
age, particularly in that of the oldest (i.e., 29-week TRAMP
mouse) (Figure 4). 12/15-LO immunostaining was predom-
inantly cytoplasmic (Figure 4), as also noted previously in
human PCa [12] and other GEM mouse lesions [5]. In
sections where PIN was focal, increased 12/15-LO immu-
nostaining was particularly correlated with areas of neoplas-
tic involvement (Figure 4). Increased expression of 12/15-LO
with tumor progression was suggested by the presence of
stronger and more uniform immunostaining in foci of un-
equivocal invasive, poorly differentiated (NE) carcinoma
(Figure 4). Such invasive poorly differentiated foci showed
4+ immunostaining in four of five mice at 18 to 29 weeks,
but one mouse without prominent immunostaining in such
invasive carcinoma (and in a lung metastasis) showed
weaker immunostaining than normal in bronchial epithelium,
raising technical concerns regarding antigen preservation
(Table 1).
This poorly differentiated carcinoma with NE features
[1] is the lesion most correlated with metastatic potential
in TRAMP [6,7]. Similar to the 12/15-LO immunostaining
in such invasive foci in the prostate, lymph node metastases
with the same NE carcinoma morphology showed uni-
form, diffuse, strong 12/15-LO immunostaining in two of
two TRAMP animals examined, one of which also showed
similarly strong expression in lung metastases. However,
12/15-LO immunostaining was weaker and somewhat more
variable in liver metastases (Table 1, Figure 4). In summary,
compared to wild-type prostate, 12/15-LO is increased in
the neoplastic epithelium of PIN in TRAMP mice, and even
more profoundly increased in the invasive and metastatic
poorly differentiated carcinoma.
Figure 2. Representative LA and AA metabolism in 20-week TRAMP mouse prostate. [14C]HODE and [14C]12/15-HETE formation in wild-type mouse prostate
(control) from 15-minute incubation with 25 M [14C]LA or [14C]AA. The solvent system consisted of a methanol/water gradient at a flow rate of 1.1 ml/min for
reverse-phase HPLC analysis, with in-line radiodetection ( Y-axis as DPM). A prominent 13-HODE peak (panel A) elutes at c20 minutes in a mixture of
two metabolites: one major metabolite coelutes atf18 minutes with standard 12-HETE, as well as a minor metabolite that coelutes atf19 minutes with standard
15-HETE (panel B) (X-axis as minutes). The unmetabolized LA and AA elutes are the prominent peaks at far right (in both panels A and B) eluting at c54 and
55 minutes, respectively. Also, a prominent peak of a mixture of prostaglandins (PGs) is seen eluting at c 6 to 7 minutes.
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Discussion
LA, followed by AA, is the major component of high-fat
western diet [24]. These dietary lipids are metabolized in
humans by cyclooxygenases (COX-1 and/or COX-2) or lip-
oxygenases (5-LO, 12-LO, 15-LO-1, and 15-LO-2). The
mouse, on the other hand, has three different 12S-lipoxyge-
nases: 1) an epidermal type (E12-LO); 2) a platelet type (P12-
LO) that is homologous to human platelet type 12-LO; and
3) a leukocyte type (L12-LO or 12/15-LO) homologous to
human 15-LO-1 [25,26]. We previously demonstrated that
the fatty acid LA metabolizing 15-LO-1 enzyme is upregu-
lated in human PCa compared to benign prostate [13]. In vitro
studies and studies with 15-LO-1 overexpressing the cell
line PC-3 in nudemice indicate that 15-LO-1 can contribute to
PCa through multiple mechanisms, including increased cell
proliferation and promotion of angiogenesis [14].
Although altered lipid metabolism by lipoxygenases and
cyclooxygenases has particularly focused exclusively on the
role of AA in human PCa development and progression,
there is now a new growing interest in the possible role of LA,
especially since our discovery that the LA-metabolizing 15-
LO-1 enzyme is high in human PCa. However, determining
the role of one or more candidate genes in PCa development
and progression and their suitability as candidate targets for
therapeutic intervention is complicated by issues such as the
difficulty in obtaining appropriate tissues from the same
patients over the long time course of PCa progression, and
the necessary duration and other complexities of conducting
clinical trials. GEM models validated for potential relevance
to at least some subsets of human PCa patients are poten-
tially extremely useful reagents used to study delineating
etiologic pathways in PCa development and progression,
and to test for effective treatments that can finally be
exploited for human applications. However, the meaningful
use of such models for translating results to human PCa will
definitely require cautious and careful validation—work that
is now ongoing in multiple laboratories. Validation criteria
include comparison of histopathologic, genetic, biochemical,
and natural history features of GEM models compared to
known aspects of human PCa, including relevant changes at
different stages of progression of this complex and hetero-
geneous neoplasm [1,3,42,43].
The widely used TRAMP model was developed by
placing the expression of the SV40 early genes under the
Figure 3. 12/15-LO enzyme activity (% conversion to metabolic product) at different time points [20 weeks (n = 5), 29 weeks (n = 5), 39 weeks (n = 5), and
49 weeks (n = 3)] with AA and LA in wild-type nontransgenic and TRAMP mouse prostates. The values for 12/15-LO are the sum of 12-HETE and 15-HETE,
respectively.
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Figure 4. Representative 12/15-LO immunostaining in TRAMP mice. (A) Positive control, showing normal cytoplasmic immunostaining in the bronchial epithelium
in the lung, with clean background in surrounding alveolated parenchyma. (B) Negative immunostaining in prostate ducts with PIN lesions (arrowheads) in 24-week
TRAMP mouse. Included are occasional foci (arrowhead) in which distinct smaller gland profiles do not as obviously connect up to the central duct lumen and
conform less obviously to the normal duct lining, raising considerations of well-differentiated adenocarcinoma. (C) Strong cytoplasmic 12/15-LO immunostaining in
stratified atypical cells in focus of PIN (*) in the prostate of 18-week TRAMP mouse. Residual (but immunonegative) normal-appearing prostate-secretory
epithelium is noted (arrowhead). (D) 12/15-LO immunostaining in focal PIN (arrowheads) in the prostate of 29-week TRAMP mouse. Residual normal prostatic
epithelium is noted (arrowhead). (E) Strong uniform 12/15-LO immunostaining in focus of PIN of 18-week TRAMP mouse. Although there are small and apparently
increased gland spaces, the connection of these to the central normal duct lining, the uniformity of this lesion, and the preservation of the normal surrounding
contractile periprostatic stroma support the designation of PIN. Other similarly involved duct/gland profiles with less prominent or absent immunostaining (e.g.,
bottom left). (F) Strong extensive 12/15-LO immunostaining in atypical epithelium (arrows) of polypoid focus of combined epithelial and stromal hyperplasia
(‘‘phyllodes like tumor’’) of 29-week TRAMP mouse. Duct lumen is toward top left. Surrounding rim of pre-existing prostatic contractile stroma is at bottom right
(arrowhead). (G) Strong, uniform 12/15-LO immunostaining in microscopic focus of invasive, poorly differentiated (NE) carcinoma (white*) in a background of
focally but less prominently immunostaining PIN in 29-week TRAMP mouse. (H) Strong, uniform, diffuse 12/15-LO immunostaining in invasive, poorly differentiated
(NE) carcinoma in the prostate of 29-week TRAMP mouse. A residual entrapped PIN containing the prostate duct is noted (*). (I) Strong, uniform, diffuse 12/15-LO
immunostaining in extensively invading, poorly differentiated (NE) carcinoma in 39-week TRAMP mouse. Tumor focus comprises areas previously referred to as
moderately differentiated and compatible with NE carcinoma in the current designation (top right), as well as areas previously referred to as poorly differentiated
carcinoma that are morphologically compatible with small cell carcinoma (bottom left), showing focal ‘‘crush’’ artifact typical of such tumors. Tumor massively
infiltrates surrounding pelvic soft tissues (adipose tissue noted*). (J) Strong, uniform 12/15-LO immunostaining in metastatic poorly differentiated (NE) carcinoma
(arrowheads) in retroperitoneal lymph node from 39-week TRAMP mouse. Immunonegative residual normal lymphoid germinal centers are noted (white*). (K)
12/15-LO immunonegative liver metastasis in 39-week TRAMP mouse. Benign liver parenchyma is seen at bottom right. (L) 12/15-LO negative lung metastasis of
poorly differentiated (NE) carcinoma (arrowheads) in 20-week TRAMP mouse. Note moderately strong positive control immunostaining in adjacent normal
bronchial epithelium (arrow). (M) Strong 12/15-LO immunostaining in lung micrometastasis (arrowhead) in 29-week TRAMP mouse.
12/15-LO in Prostate Tumors of TRAMP Mice Kelavkar et al. 827
Neoplasia . Vol. 6, No. 6, 2004
temporally and spatially restricted prostate-specific control of
the minimal rat probasin promoter [6]. The prostate epithelial
expression of T antigen sequesters p53 and pRB, which
have been implicated in human PCa, includes early, low-
stage PCa and subsets of HGPIN, as well as advanced PCa
[1,6]. PCa development and progression in TRAMP mice
mimic certain key aspects of the natural history of the human
clinical disease. In TRAMP, as early as 6 to 12 weeks of age,
the prostate glands display mild to severe hyperplasia of
the prostate epithelium, resembling PIN, and by 30 weeks of
age, 100% of TRAMP mice display primary and metastatic
PCa [1,6]. In the current study, we demonstrate that similar
to human PCa, the development and progression of PCa in
TRAMP are accompanied by increased expression of the
murine 12/15-LO homologue of the lipid-metabolizing en-
zyme, 15-LO-1. Given the multiple potential mechanisms
whereby this attractive pharmacologic target may contribute
to PCa [13,14], these results further support the potential use
of GEM in elucidating the role of LA- and AA-metabolizing
enzymes in PCa development and progression, and specif-
ically the use of TRAMP to further determine the etiologic
contribution of the 12/15-LO to PCa progression. This is
further significant, in part, because pharmacologic inhibitors
and other strategies for reducing 12/15-LO (15-LO-1) exist,
and because the TRAMP model has a reproducible natural
history that allows for histopathologic and other relevant
natural history parameters to be readily employed in inter-
vention studies [2,3,4,7].
Kasper et al. [8] recently showed that PIN and PCa
development in the LPB-Tag GEM model was accompanied
by increased expression of the murine 12/15-LO or leukocyte
12-LO [40]. LPB-Tag prostates made substantially more
12-HETE from AA than wild-type prostates, with enzymatic
properties typical of the 12/15-LO (leukocyte 12-LO), and
mRNA and immunostaining showed increased expression of
the leukocyte 12-LO, but not the platelet 12-LO. The 12/15-
LO was increased in PIN, and invasive and metastatic
carcinoma [40]. This murine enzyme, demonstrated to be
increased in TRAMP tumors in the current study, differs
from the human 15-LO-1 by apparently making much more
12-HETE than 15-HETE from AA [40]. In contrast to putative
tumor-suppressive properties of 15-HETE in the human
prostate [18,36,37], 12-HETE has been shown to possibly
contribute to PCa progression, including by promotion of
angiogenesis [11]. Although 15-LO-2 is found in the normal
human prostate, its mouse ortholog, 8-LO, is absent in the
normal mouse prostate [25,40]. Interestingly, the most pre-
ferred substrate for 15-LO-2 in humans and 8-LO in the mice
is AA versus LA [40].
Thus, it is now becoming increasingly clear that that LA,
and not AA, plays a major role in the process of carcino-
genesis particularly in humans, wherein alterations in the
pro–carcinogeniclipoxygenases (i.e., 15-LO-1) and anti–
carcinogenic lipoxygenases (i.e., 15-LO-2) could contribute
to PCa [13,14,15,37]. Therefore, it is reasonable to conclude
that the overexpression of 12/15-LO in GEM models of PCa,
and 15-LO-1 in human PCa, in conjunction with LA-rich fat
diet, can cause prostate tumorigenesis.
Although 12/15-LO–derived 12-HETE could contribute to
PCa development and progression in TRAMP, recent stud-
ies showing that the preferred substrate for 15-LO-1 is LA
rather than AA [13,22] suggest the need for increased
attention on the possible pro–neoplastic role of 15-LO-1
metabolism of LA to 13-HODE. Similar to the human
15-LO-1, the murine 12/15-LO makes 13-HODE from LA
[22]. To our knowledge, our current study is the first to
demonstrate the increased capacity for 13-HODE synthesis
in a neoplastic GEM versus wild-type mouse prostate. Mul-
tiple possible mechanisms have been proposed for the
contribution of (human) 15-LO-1 and 13-HODE to tumor
progression, including promotion of tumor growth and spread
by induction of angiogenesis through increased vascular
endothelial growth factor [13] and upregulation of insulin-like
growth factor receptor (IGF-1R) activated by the mitogen-
activated protein kinase pathway [44]. Studies have also
suggested a pro–neoplastic effect of 15-LO-1–derived
13-HODE (but not the 15-LO-2–derived AA metabolite,
15-HETE) through downregulation of PPARg by interaction
with epidermal growth factor (EGF) and phosphorylation of
PPARg mediated by activated mitogen-activated protein
kinase [36]. Hence, the results of our study suggest that
GEM models of PCa and the TRAMP model specifically
Table 1. Immunohistochemistry with 12-LO Antibody, and Pathologic Description in Prostates of Aging TRAMP Mice.
Mouse Age (weeks) PIN Epithelial Stromal Hyperplasia Invasive Poorly Differentiated (NE)
Carcinoma
Lymph Node
Metastases
Liver
Metastases
Lung
Metastases
18 0 0 – * – – –
18 1–2+y – – – – –
18 1+ – 4+ – – –
20 0–1+ – 0 – – 0z
22 – – 4+ 4+ – –
24 0 – 4+ – – –
29 3+ 3+ 4+ 4+ 2+§ 4+
39 – 0 – – 0b 2+#
(+) Positive 12-LO staining; () either negative 12-LO staining, or staining is not observed.
*Not present in sections examined, thus was not evaluated for immunostaining.
yRanges reflect difference in separate prostatic lobes examined.
zWeaker than usual immunostaining of internal control benign bronchial epithelium in section with lung metastasis.
§Foci consistent with focally positive liver micrometastases.
bFour metastatic foci, all negative.
#Seven of nine essentially negative micrometastases; two were weekly positive.
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may be useful for delineating how dietary lipids implicated in
human PCa and their metabolism by 15-LO-1 can contribute
to PCa development and progression.
One long-term goal of these and related studies is to
provide a mechanism that explains the observation that diets
high in fat and aberrant expression of 15-LO-1 are associat-
ed with an increased risk of PCa. Although our studies do
not exclude a role for E12-LO and P12-LO in the increased
AA-derived 12-HETE, the results of our enzyme and immu-
nohistochemical studies certainly demonstrate the increased
expression of the 12/15-LO and its ability to form LA-derived
13-HODE. Although altered lipid metabolism by LOs and
COXs has particularly focused on the role of AA in human
PCa development and progression, there is a new growing
interest in the possible role of LA metabolism in PCa,
especially since our discovery of high levels of 15-LO-1
associated with PCa [13], followed by the biologic role [44]
and evidence of its pro–proliferative role in vivo using a
human PCa cell line [14]. In this regard, it is extremely
interesting that this gene is increased in two different GEM
models of PCa: the LPB-Tag model [40] and TRAMP model
(this study). In both models, 12/15-LO appears to be in-
creased in PIN, and invasive and metastatic carcinoma. This
is potentially significant, at least in part, as these are two
fundamentally different models [1]. Likely as a consequence
of these fundamental model differences, the GEM models
develop distinct phenotypes and natural histories. Hence,
that the 12/15-LO homologue of the human 15-LO-1 is
increased with PIN and invasive and metastatic PCa in both
models strongly suggests that it may contribute fundamen-
tally to PCa development and progression.
In summary, our initial studies characterizing LA and AA
metabolism in the TRAMP mouse have demonstrated an
increased expression of 12/15-LO in TRAMP PCa develop-
ment, similar to that noted in human PCa. Regardless of
the precise relationship between 15-LO-1 overexpression in
HGPIN and/or invasive PCa in human PCa and in PIN
and PCa in the TRAMP model, the increased expression of
12/15-LO in this model will allow for additional elucidation of
the mechanisms whereby this enzyme and its metabolites
may contribute to tumor development and progression.
Given the availability of inhibitors and/or knockout mice for
this specific gene, GEMmodels may be useful for elucidating
the contribution of 15-LO-1 to ascertain its role in human PCa
and its suitability as a target for therapy or chemoprevention.
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